- Home
- ELDN vs VSTM Comparison
ELDN vs VSTM Comparison
Compare ELDN & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELDN
- VSTM
- Stock Information
- Founded
- ELDN 2004
- VSTM 2010
- Country
- ELDN United States
- VSTM United States
- Employees
- ELDN N/A
- VSTM N/A
- Industry
- ELDN Biotechnology: Pharmaceutical Preparations
- VSTM Biotechnology: Pharmaceutical Preparations
- Sector
- ELDN Health Care
- VSTM Health Care
- Exchange
- ELDN Nasdaq
- VSTM Nasdaq
- Market Cap
- ELDN 140.3M
- VSTM 132.0M
- IPO Year
- ELDN N/A
- VSTM 2012
- Fundamental
- Price
- ELDN $4.07
- VSTM $3.93
- Analyst Decision
- ELDN Strong Buy
- VSTM Strong Buy
- Analyst Count
- ELDN 1
- VSTM 8
- Target Price
- ELDN $16.00
- VSTM $14.57
- AVG Volume (30 Days)
- ELDN 1.0M
- VSTM 944.1K
- Earning Date
- ELDN 11-12-2024
- VSTM 11-06-2024
- Dividend Yield
- ELDN N/A
- VSTM N/A
- EPS Growth
- ELDN N/A
- VSTM N/A
- EPS
- ELDN N/A
- VSTM N/A
- Revenue
- ELDN N/A
- VSTM $10,000,000.00
- Revenue This Year
- ELDN N/A
- VSTM N/A
- Revenue Next Year
- ELDN N/A
- VSTM $108.05
- P/E Ratio
- ELDN N/A
- VSTM N/A
- Revenue Growth
- ELDN N/A
- VSTM N/A
- 52 Week Low
- ELDN $1.11
- VSTM $2.10
- 52 Week High
- ELDN $5.54
- VSTM $14.22
- Technical
- Relative Strength Index (RSI)
- ELDN 51.95
- VSTM 54.97
- Support Level
- ELDN $3.76
- VSTM $3.71
- Resistance Level
- ELDN $4.17
- VSTM $4.29
- Average True Range (ATR)
- ELDN 0.39
- VSTM 0.36
- MACD
- ELDN -0.15
- VSTM -0.05
- Stochastic Oscillator
- ELDN 18.45
- VSTM 34.09
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.